Compare Gen Digital Inc. Common Stock (GEN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gen Digital Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Gen Digital Inc. Common Stock trades at $23.73 (market cap $14.25B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: Gen Digital Inc. Common Stock is far larger — about 3.8× Tango Therapeutics Inc.'s market cap, and Gen Digital Inc. Common Stock pays a 2.1% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gen Digital Inc. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| GEN | TNGX | |
|---|---|---|
Market Cap | $14.25B | $3.74B |
Volume | 6,755,379 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $31.41 | $32.90 |
52-Week Low | $17.89 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $21.89B | $2.76B |
Dividend Yield | 2.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEN Digital Inc. (GEN) trades at $23.81, up 1.97% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 13.92, net income margin of 20.73%, and robust cash flow from operations of $1.22B in 2025. Recent news highlights include a takeover bid for GoDaddy and participation in investor conferences, reflecting strategic moves in the cybersecurity and digital services sector.
The outlook is mixed: analyst consensus targets $25.50 with a balanced buy/hold split, but technical indicators suggest near-term pressure. Key risks include high debt levels and integration challenges from acquisitions. Earnings growth and market expansion into AI services present opportunities, though volatility may persist amid competitive and macroeconomic headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gen Digital Inc. Common Stock
Gen Digital provides cybersecurity, online privacy, identity protection, and financial wellness services. Its consumer brands include Norton, Avast, LifeLock, and MoneyLion.
Read more on GEN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
